South Korea · Delayed Price · Currency is KRW HLB Genex Statistics
Total Valuation
HLB Genex has a market cap or net worth of KRW 72.43 billion. The enterprise value is 99.01 billion.
| Market Cap | 72.43B |
| Enterprise Value | 99.01B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HLB Genex has 32.55 million shares outstanding. The number of shares has increased by 93.73% in one year.
| Current Share Class | 32.55M |
| Shares Outstanding | 32.55M |
| Shares Change (YoY) | +93.73% |
| Shares Change (QoQ) | -43.59% |
| Owned by Insiders (%) | 12.18% |
| Owned by Institutions (%) | 2.01% |
| Float | 21.68M |
Valuation Ratios
The trailing PE ratio is 3.83.
| PE Ratio | 3.83 |
| Forward PE | n/a |
| PS Ratio | 1.63 |
| PB Ratio | 1.36 |
| P/TBV Ratio | 3.01 |
| P/FCF Ratio | 24.76 |
| P/OCF Ratio | 17.13 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.72, with an EV/FCF ratio of 33.85.
| EV / Earnings | 4.62 |
| EV / Sales | 2.23 |
| EV / EBITDA | 18.72 |
| EV / EBIT | 120.38 |
| EV / FCF | 33.85 |
Financial Position
The company has a current ratio of 0.82, with a Debt / Equity ratio of 0.86.
| Current Ratio | 0.82 |
| Quick Ratio | 0.69 |
| Debt / Equity | 0.86 |
| Debt / EBITDA | 7.68 |
| Debt / FCF | 15.62 |
| Interest Coverage | 0.13 |
Financial Efficiency
Return on equity (ROE) is 53.91% and return on invested capital (ROIC) is 2.17%.
| Return on Equity (ROE) | 53.91% |
| Return on Assets (ROA) | 0.67% |
| Return on Invested Capital (ROIC) | 2.17% |
| Return on Capital Employed (ROCE) | 2.02% |
| Weighted Average Cost of Capital (WACC) | 12.01% |
| Revenue Per Employee | 591.28M |
| Profits Per Employee | 285.51M |
| Employee Count | 75 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 4.35 |
Taxes
In the past 12 months, HLB Genex has paid 916.70 million in taxes.
| Income Tax | 916.70M |
| Effective Tax Rate | 4.05% |
Stock Price Statistics
The stock price has decreased by -36.23% in the last 52 weeks. The beta is 0.03, so HLB Genex's price volatility has been lower than the market average.
| Beta (5Y) | 0.03 |
| 52-Week Price Change | -36.23% |
| 50-Day Moving Average | 2,614.70 |
| 200-Day Moving Average | 2,831.73 |
| Relative Strength Index (RSI) | 39.49 |
| Average Volume (20 Days) | 137,526 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HLB Genex had revenue of KRW 44.35 billion and earned 21.41 billion in profits. Earnings per share was 580.81.
| Revenue | 44.35B |
| Gross Profit | 15.81B |
| Operating Income | 1.48B |
| Pretax Income | 22.62B |
| Net Income | 21.41B |
| EBITDA | 5.95B |
| EBIT | 1.48B |
| Earnings Per Share (EPS) | 580.81 |
Balance Sheet
The company has 33.12 billion in cash and 45.70 billion in debt, with a net cash position of -12.58 billion or -386.53 per share.
| Cash & Cash Equivalents | 33.12B |
| Total Debt | 45.70B |
| Net Cash | -12.58B |
| Net Cash Per Share | -386.53 |
| Equity (Book Value) | 53.43B |
| Book Value Per Share | 1,354.85 |
| Working Capital | -11.39B |
Cash Flow
In the last 12 months, operating cash flow was 4.23 billion and capital expenditures -1.30 billion, giving a free cash flow of 2.93 billion.
| Operating Cash Flow | 4.23B |
| Capital Expenditures | -1.30B |
| Depreciation & Amortization | 4.47B |
| Net Borrowing | -3.69B |
| Free Cash Flow | 2.93B |
| FCF Per Share | 89.85 |
Margins
Gross margin is 35.65%, with operating and profit margins of 3.34% and 48.29%.
| Gross Margin | 35.65% |
| Operating Margin | 3.34% |
| Pretax Margin | 51.00% |
| Profit Margin | 48.29% |
| EBITDA Margin | 13.41% |
| EBIT Margin | 3.34% |
| FCF Margin | 6.60% |
Dividends & Yields
HLB Genex does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -93.73% |
| Shareholder Yield | -93.73% |
| Earnings Yield | 29.56% |
| FCF Yield | 4.04% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on March 19, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Mar 19, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
HLB Genex has an Altman Z-Score of 0.93 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.93 |
| Piotroski F-Score | 4 |